© 1993 Oxford University Press
research-article |
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
Divisions of Nutritional Carcinogenesis, American Health Foundation Valhalla, NY 10595
1Divisions of Pathology and Toxicology, American Health Foundation Valhalla, NY 10595
2Chemoprevention Branch, Division of Cancer Control and Prevention, National Cancer Institute Bethesda, MD 20856, USA
Epidemiologic studies suggest that sustained use of aspirin may reduce the risk of development of and mortality due to colon cancer. Previous preclinical studies have shown that several non-steroidal anti-inflammatory drugs act as potential chemopreventive agents in experimentally induced colon cancer models. The present study was designed to investigate the chemopreventive effect of 40 and 80% maximum tolerated dose (MTD) levels of aspirin administered in the diet on azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. The MTD of aspirin as determined in male F344 rats was 500 p.p.m. Beginning at 5 weeks of age, all animals were randomly divided into various experimental groups (48 rats/group) and fed one of the semipurified diets containing 0, 200 p.p.m. (40% MTD), or 400 ppm (80% MTD) of aspirin. Two weeks later, all animals (36 rats/group) except the vehicle-treated groups (12 rats/group) were administered s.c. injections of AOM at a dose level of 15 mg/kg body wt, once weekly for 2 weeks. All animals were continued on their respective dietary regimen for additional 52 weeks and necropsied. Histopathologic evaluation of colon tumors was performed by routine procedures. Basal levels and ex vivo production of colonic mucosal and tumor prostaglandin E2 (PGE2) were measured in all groups. The results indicate that daily oral administration of 200 and 400 p.p.m. aspirin significantly inhibited the incidence (% animals with tumors) and multiplicity (tumors/animal) of invasive adenocarcinomas of the colon as well as the size of adenocarcinomas. Colonic mucosal and tumor PGE2 levels (basal and ex vivo production) were significantly reduced in animals administered 200 and 400 p.p.m. aspirin. The results of this study support the epidemiologic evidence that ingestion of aspirin inhibits colon carcinogenesis. Although the precise mechanisms of aspirin-induced colon tumor inhibition remain to be determined, it is likely that the effect may be mediated through the modulation of prostaglandin synthesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. E. Steele, C. V. Rao, Y. Zhang, J. Patlolla, D. Boring, L. Kopelovich, M. M. Juliana, C. J. Grubbs, and R. A. Lubet Chemopreventive Efficacy of Naproxen and Nitric Oxide-naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers Cancer Prevention Research, November 1, 2009; 2(11): 951 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Liou, C.-C. Wu, B.-R. Chen, L. B. Yen, and K. K. Wu Nonsteroidal Anti-Inflammatory Drugs Induced Endothelial Apoptosis by Perturbing Peroxisome Proliferator-Activated Receptor-{delta} Transcriptional Pathway Mol. Pharmacol., November 1, 2008; 74(5): 1399 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Allred, D. R. Talbert, R. C. Southard, X. Wang, and M. W. Kilgore PPAR{gamma}1 as a Molecular Target of Eicosapentaenoic Acid in Human Colon Cancer (HT-29) Cells J. Nutr., February 1, 2008; 138(2): 250 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tsuneoka, Y. Tajima, A. Kitazato, K. Fukuda, T. Kitajima, T. Kuroki, S. Onizuka, and T. Kanematsu Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters Carcinogenesis, February 1, 2005; 26(2): 465 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Shoji, M Takahashi, T Kitamura, K Watanabe, T Kawamori, T Maruyama, Y Sugimoto, M Negishi, S Narumiya, T Sugimura, et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development Gut, August 1, 2004; 53(8): 1151 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Hull, S. C.W. Ko, and G. Hawcroft Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol. Cancer Ther., August 1, 2004; 3(8): 1031 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin Carcinogenesis, May 1, 2004; 25(5): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Shpitz, E Klein, G Buklan, D Neufeld, A Nissan, H R Freund, M Grankin, and J Bernheim Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer Gut, November 1, 2003; 52(11): 1598 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Zhu and E. L. Schwartz Expression of the Angiogenic Factor Thymidine Phosphorylase in THP-1 Monocytes: Induction by Autocrine Tumor Necrosis Factor-{alpha} and Inhibition by Aspirin Mol. Pharmacol., November 1, 2003; 64(5): 1251 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis, May 1, 2003; 24(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E.M. Dommels, M. M.G. Haring, N. G.M. Keestra, G. M. Alink, P. J. van Bladeren, and B. van Ommen The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE2 synthesis and cytotoxicity in human colorectal carcinoma cell lines Carcinogenesis, March 1, 2003; 24(3): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sample, M. Wargovich, S. M. Fischer, N. Inamdar, P. Schwartz, X. Wang, K.-A. Do, F. A. Sinicrope, N. E. Day, D. E. G. Shuker, et al. A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.R. Paterson and J.R. Lawrence Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer QJM, August 1, 2001; 94(8): 445 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vogiagis, W. Brown, E. M. Glare, and P. E. O'Brien Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels Carcinogenesis, June 1, 2001; 22(6): 869 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tang, M. Gonzales, H. Inoue, and G. T. Bowden Roles of Akt and Glycogen Synthase Kinase 3{beta} in the Ultraviolet B Induction of Cyclooxygenase-2 Transcription in Human Keratinocytes Cancer Res., June 1, 2001; 61(11): 4329 - 4332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Krishnan, M. T. Ruffin, D. Normolle, I. Shureiqi, K. Burney, J. Bailey, M. Peters-Golden, C. L. Rock, C. R. Boland, and D. E. Brenner Colonic Mucosal Prostaglandin E2 and Cyclooxygenase Expression before and after Low Aspirin Doses in Subjects at High Risk or at Normal Risk for Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 447 - 453. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Li, X. Wu, and X.-C. Xu Induction of Apoptosis in Colon Cancer Cells by Cyclooxygenase-2 Inhibitor NS398 through a Cytochrome c-dependent Pathway Clin. Cancer Res., April 1, 2001; 7(4): 1010 - 1016. [Abstract] [Full Text]
|
|
|
|
|
|
R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]
|
|
|
|
|
|
Y Kishimoto, N Takata, T Jinnai, T Morisawa, G Shiota, H Kawasaki, and J Hasegawa Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane Gut, December 1, 2000; 47(6): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, L. A. Cohen, B. Simi, I. Cooma, and C. V. Rao Preventive Potential of Wheat Bran Fractions against Experimental Colon Carcinogenesis: Implications for Human Colon Cancer Prevention Cancer Res., September 1, 2000; 60(17): 4792 - 4797. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Ogura, S. Matsuda, M. Ito, R. Niimi, M. Sumitomo, and Y. Kawarada Chemoprevention of biliary carcinogenesis in Syrian hamsters by the novel carboxamide derivative IS-741 after initiation with N-nitrosobis(2-oxopropyl)amine (BOP) Carcinogenesis, August 1, 2000; 21(8): 1469 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shureiqi, D. Chen, J. J. Lee, P. Yang, R. A. Newman, D. E. Brenner, R. Lotan, S. M. Fischer, and S. M. Lippman 15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells J Natl Cancer Inst, July 19, 2000; 92(14): 1136 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Steinbach, P. M. Lynch, R. K.S. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis N. Engl. J. Med., June 29, 2000; 342(26): 1946 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J S Langman, K K Cheng, E A Gilman, and R J Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ, June 17, 2000; 320(7250): 1642 - 1646. [Abstract] [Full Text]
|
|
|
|
|
|
H-H. S. Chow, D. L. Earnest, D. Clark, N. Mason-Liddil, C. B. Kramer, J. G. Einspahr, J. M. Guillen-Rodriguez, D. J. Roe, W. Malone, J. A. Crowell, et al. Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 351 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy Novel Approaches to the Prevention of Colon Cancer by Nutritional Manipulation and Chemoprevention Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 239 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, and C. V. Rao Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis Cancer Res., January 1, 2000; 60(2): 293 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
J J Keller, G J A Offerhaus, M Polak, S N Goodman, M L Zahurak, L M Hylind, S R Hamilton, and F M Giardiello Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac Gut, December 1, 1999; 45(6): 822 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, T. Kawamori, R. Lubet, V. Steele, G. Kelloff, and C. V. Rao Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis Carcinogenesis, August 1, 1999; 20(8): 1645 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process Cancer Res., July 1, 1999; 59(14): 3387 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, H. A.J. Schut, P. Conran, P. M. Kramer, R. A. Lubet, V. E. Steele, E. E. Hawk, G. J. Kelloff, and M. A. Pereira Prevention by aspirin and its combination with {alpha}-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis, March 1, 1999; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawamori, R. Lubet, V. E. Steele, G. J. Kelloff, R. B. Kaskey, and C. V. Rao Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer Cancer Res., February 1, 1999; 59(3): 597 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao, H. Sheng, R. Aramandla, M. A. Pereira, R. A. Lubet, E. Hawk, L. Grogan, I. R. Kirsch, M. K. Washington, R. D. Beauchamp, et al. Coordinate regulation of cyclooxygenase-2 and TGF-ß1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors Carcinogenesis, February 1, 1999; 20(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Coffey, C. J. Hawkey, L. Damstrup, R. Graves-Deal, V. C. Daniel, P. J. Dempsey, R. Chinery, S. C. Kirkland, R. N. DuBois, T. L. Jetton, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells PNAS, January 21, 1997; 94(2): 657 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giovannucci, K. M. Egan, D. J. Hunter, M. J. Stampfer, G. A. Colditz, W. C. Willett, and F. E. Speizer Aspirin and the Risk of Colorectal Cancer in Women N. Engl. J. Med., September 7, 1995; 333(10): 609 - 614. [Abstract] [Full Text] [PDF]
|
|